Cardioonc Bot
@Cardioonc_bot
Followers
771
Following
24
Media
1
Statuses
35K
unable to do my job since @TwitterDev just made getting #cardioonc information out to you $5,000. Cannot afford so bidding farewell.
Joined October 2019
"Kindly participate in our voluntary survey on cardio-oncology education! Your input will help us identify gaps in training and develop better educational content for healthcare providers. Contribute to advancing cardio-oncology knowledge!" >> https://t.co/6yZsn5pH1b
3
23
22
Remote ischemic conditioning does not exhibit cardioprotective effects in childhood cancer patients receiving anthracycline-based chemotherapy. https://t.co/KJD2xLDjLK
#JACCCardioOnc #CardioOnc #Anthracycline #ayacsm #childhoodcancer #cvPed #CardioTwitter
0
9
28
@MayoPCCM faculty #DrTimothyAksamit and colleagues performed an #ArtificialIntelligence augmented propensity score looking into clinical, cost-effectiveness and ethical analysis of #cardiooncology cardiac arrests related mortality and disparities. #MedEd
https://t.co/Oth1fraRxO
pubmed.ncbi.nlm.nih.gov
Background and objectives: Little is known about outcome improvements and disparities in cardiac arrest and active cancer. We performed the first known AI and propensity score (PS)-augmented clinic...
0
1
0
Artificial intelligence and CardioOncology 👇 @ICOSociety @Puls_Medycyny @MonikMajewska @k_matusewicz
🤖🩺Sztuczna inteligencja #AI pomoże zmniejszyć obciążenie pracowników sektora opieki zdrowotnej i obniżyć koszty. Jednak powinna być traktowana jako narzędzie wspomagające. Nie zastąpi lekarzy i pielęgniarek, mówi dr @DrRowIlling z @awscloud
https://t.co/57U3AkGJVq
0
2
4
0
1
1
4/ CS can be classified into 2 types in the new cardio-oncology syndrome classification (@ICOSociety) Type 1 CS caused by cancer itself or indirectly through increased coronary risk, thromboembolic events, tamponade, or paraneoplastic syndrome. https://t.co/hh6cN0aYT0
cardiooncologyjournal.biomedcentral.com
Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology...
1
3
14
Another brick in the wall on the understanding of ICI mediated cardiovascular toxicities @CardioOncology @WCFWMeijers #cardiooncology #immunotherapy #vasculitis. CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis | Circulation Research
ahajournals.org
BACKGROUND: Giant cell arteritis (GCA) causes severe inflammation of the aorta and its branches and is characterized by intense effector T-cell infiltration. The roles that immune checkpoints play in...
2
7
17
Hot off the press! Biomarkers are crucial in the diagnosis of ICI myotoxicity. This review goes through the most recent data and provides guidance on their use. #cardioonc @umichCVC @DrJESalem @Avasbind @anisi_a_ismail
https://t.co/pMPQR6cwKz
link.springer.com
Current Cardiology Reports - Immune checkpoint inhibitor (ICI)-related myocarditis poses a major clinical challenge given its non-specific presentation, rapid progression, and high mortality rate....
0
5
24
Are we close to unravel underlying mechanisms and targets for cardio-oncology patients? How do we need to use biomarkers in this field? New insights in JACC: CO https://t.co/qzfZ2wMj0L
@JACCJournals @ICOSociety @rudolf_deboer @CardioOncology @Joseph_pierre_ @ErasmusMC
jacc.org
0
3
10
"Kickstart #GCOS23 Day 1 with a Research Symposium and keynote by @FusterValentin! Bonnie Ky & Carlo Tocchetti spearhead the 1st session. @SALLOUMFN navigates cardio toxicities prevention, then Dr. Kitsis discusses new mitochondrial therapies. Brace yourselves!"@ICOSociety
1
14
35
A #JACCCardioOnc study found that anticoagulants do not decrease the risk of ATEs for ambulatory cancer patients on systemic therapy. Read more in @CancerTherAdvsr: https://t.co/dKyqpfTKjz
#cvCoag
cancertherapyadvisor.com
Anticoagulants do not reduce the risk of arterial thrombotic events in ambulatory cancer patients on systemic therapy, a review suggests.
0
2
0
.@mmamas1973 thank you for providing one of the most timely and important lectures on treating cardiovascular disease in the oncology patient today. One of the best lectures I’ve ever had the privilege of attending. #CardioOnc @ACCinTouch
1
4
9
1/🔥 off the press. Had the pleasure of writing an editorial on an interesting paper characterizing PH phenotypes in patients with #mpnsm in @ATSBlueEditor with @GabyHobbs and @bdgarcia. Great 🫀🫁🩸 collaboration. #cardioonc #cardioheme. A short🧵 https://t.co/rl16r7J34z
2
4
15
"Day 1, Session 2 of the Research Symposium highlights international collaboration in anthracycline cardiotoxicity. Explore two key initiatives: the RESILIENCE Project and the Leducq Network of Excellence-funded research. Dive in with us, and stay updated @ICOSSOCIETY!"#GCOS23
1
20
35
Calling all cardio-oncology enthusiasts for abstracts and registration! The first of its kind, translational #CardioOnc symposium by Dr. Andreas Beyer and team via American Physiological Society!
2
13
18
Remote ischemic conditioning does not exhibit cardioprotective effects in childhood cancer patients receiving anthracycline-based chemotherapy. https://t.co/KJD2xLDjLK
#JACCCardioOnc #CardioOnc #Anthracycline #ayacsm #childhoodcancer #cvPed #CardioTwitter
0
9
28
Cachexia for the Cardio-Oncologist: "Hot-of-the-Press" & Ideas for Further Research #CardioOnc @ICOS @EuroCardioOnc @JACCJournals @OSUWexMed @Nature @SABOURETCardio
0
2
1